Northwestern Mutual Investment Management Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.04M Buy
8,137
+10
+0.1% +$4.43K 0.05% 129
2026
Q1
$3.63M Buy
8,127
+20
+0.2% +$9.33K 0.06% 126
2025
Q4
$3.68M Sell
8,107
-64
-0.8% -$27.6K 0.04% 126
2025
Q3
$3.2M Sell
8,171
-22
-0.3% -$9.19K 0.05% 150
2025
Q2
$3.65M Buy
8,193
+26
+0.3% +$12K 0.06% 113
2025
Q1
$3.96M Sell
8,167
-10
-0.1% -$4.66K 0.06% 90
2024
Q4
$3.29M Sell
8,177
-4
-0% -$1.85K 0.07% 115
2024
Q3
$3.8M Sell
8,181
-32
-0.4% -$15.4K 0.09% 92
2024
Q2
$3.85M Buy
8,213
+35
+0.4% +$15.2K 0.1% 88
2024
Q1
$3.42M Buy
8,178
+21
+0.3% +$8.88K 0.09% 104
2023
Q4
$3.32M Buy
8,157
+11
+0.1% +$4.06K 0.09% 93
2023
Q3
$2.83M Buy
8,146
+22
+0.3% +$7.69K 0.08% 99
2023
Q2
$2.86M Buy
8,124
+43
+0.5% +$14.5K 0.07% 105
2023
Q1
$2.55M Buy
8,081
+36
+0.4% +$10.8K 0.07% 113
2022
Q4
$2.32M Sell
8,045
-1,481
-16% -$451K 0.06% 108
2022
Q3
$2.76M Sell
9,526
-1,815
-16% -$522K 0.07% 94
2022
Q2
$3.2M Buy
11,341
+78
+0.7% +$20.9K 0.07% 100
2022
Q1
$2.94M Sell
11,263
-1,353
-11% -$321K 0.07% 133
2021
Q4
$2.77M Sell
12,616
-382
-3% -$74.3K 0.05% 162
2021
Q3
$2.36M Buy
12,998
+1,242
+11% +$242K 0.05% 168
2021
Q2
$2.37M Sell
11,756
-29
-0.2% -$6.07K 0.04% 169
2021
Q1
$2.53M Sell
11,785
-2,486
-17% -$546K 0.04% 150
2020
Q4
$3.37M Buy
14,271
+27
+0.2% +$6.2K 0.04% 164
2020
Q3
$4.13M Hold
14,244
0.06% 108
2020
Q2
$4.13M Buy
14,244
+844
+6% +$229K 0.06% 105
2020
Q1
$3.19M Buy
13,400
+3,410
+34% +$782K 0.05% 114
2019
Q4
$2.19M Buy
9,990
+202
+2% +$40.9K 0.04% 195
2019
Q3
$1.66M Buy
9,788
+73
+0.8% +$12.9K 0.04% 269
2019
Q2
$1.78M Sell
9,715
-29,134
-75% -$5.09M 0.04% 233
2019
Q1
$7.15M Buy
38,849
+335
+0.9% +$61.9K 0.13% 141
2018
Q4
$6.38M Sell
38,514
-6,207
-14% -$1.08M 0.11% 147
2018
Q3
$8.62M Sell
44,721
-4,077
-8% -$726K 0.13% 142
2018
Q2
$8.29M Buy
48,798
+2,583
+6% +$400K 0.12% 156
2018
Q1
$7.53M Sell
46,215
-10,909
-19% -$1.78M 0.13% 150
2017
Q4
$8.56M Buy
57,124
+599
+1% +$88.7K 0.14% 148
2017
Q3
$8.59M Sell
56,525
-630
-1% -$94.8K 0.14% 141
2017
Q2
$7.37M Buy
57,155
+6,935
+14% +$835K 0.12% 161
2017
Q1
$5.49M Buy
50,220
+36,851
+276% +$3.24M 0.1% 185
2016
Q4
$985K Sell
13,369
-11,145
-45% -$907K 0.02% 498
2016
Q3
$2.14M Buy
24,514
+15,079
+160% +$1.43M 0.05% 235
2016
Q2
$812K Buy
9,435
+28
+0.3% +$2.42K 0.02% 367
2016
Q1
$748K Buy
9,407
+73
+0.8% +$6.6K 0.02% 388
2015
Q4
$1.17M Buy
9,334
+322
+4% +$38.9K 0.02% 329
2015
Q3
$939K Buy
9,012
+57
+0.6% +$7.32K 0.02% 382
2015
Q2
$1.11M Sell
8,955
-25,997
-74% -$3.28M 0.02% 374
2015
Q1
$4.12M Buy
+34,952
New +$4.19M 0.08% 157

Other funds holding VRTX

Northwestern Mutual Investment Management Company's VRTX Position: Q2 2026 in Review

Northwestern Mutual Investment Management Company increased its Vertex Pharmaceuticals (VRTX) stake by 0.12% in Q2 2026, buying an estimated $4.43K and bringing the position to 8,137 shares worth $4.04M. The position accounts for 0.05% of the portfolio, ranked #129.

Northwestern Mutual Investment Management Company first reported a position in VRTX in Q1 2015 and has held it in 46 quarters since. The position peaked at $8.62M in Q3 2018. 1,304 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Northwestern Mutual Investment Management Company held 8,137 shares of Vertex Pharmaceuticals worth $4.04M as of Q2 2026.
  • Northwestern Mutual Investment Management Company bought 10 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.43K.
  • Vertex Pharmaceuticals made up 0.05% of Northwestern Mutual Investment Management Company's portfolio in Q2 2026, its #129 holding.
  • Northwestern Mutual Investment Management Company first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 46 quarters since.
  • Northwestern Mutual Investment Management Company's Vertex Pharmaceuticals position peaked at $8.62M in Q3 2018.
  • 1,304 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Northwestern Mutual Investment Management Company's 13F filing for Q2 2026, filed 12 Aug 2026.